Brief: Algernon Pharmaceuticals Enters Into A Clinical Trial Agreement With Yale University For A Dmt Phase 2 Depression Study

Grey Matters Health

24/10/2022 13:50

Oct 24 (Reuters) - Algernon Pharmaceuticals Inc
 AGN.CD :
    * ALGERNON PHARMACEUTICALS ENTERS INTO A CLINICAL TRIAL
AGREEMENT
WITH YALE UNIVERSITY FOR A DMT PHASE 2 DEPRESSION STUDY
    * ALGERNON PHARMACEUTICALS INC - AS PART OF CTA, ALGERNON
WILL
PROVIDE CGMP DMT FOR STUDY
    * ALGERNON PHARMACEUTICALS - WILL JOINTLY OWN INTELLECTUAL
PROPERTY AROUND CLINICAL USE OF DMT ARISING FROM STUDY DEVELOPED
JOINTLY BY ALGERNON AND YALE
    * ALGERNON PHARMACEUTICALS INC - WILL RECEIVE DATA FROM
STUDY,
WHICH MAY ASSIST IN ITS DMT STROKE RESEARCH PROGRAM
    * ALGERNON PHARMACEUTICALS - WILL HAVE OPTION TO NEGOTIATE
LICENSES TO BOTH IP DEVELOPED JOINTLY AND IP DEVELOPED SOLELY BY
YALE

Source text for Eikon:  ID:nGNX8NXn0T 
Further company coverage:  AGN.CD 
 ((Reuters.Briefs@thomsonreuters.com;))